3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年6月30日) | 当連結会計年度 (2025年6月30日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 4,790,024 | 4,958,351 |
受取手形、売掛金及び契約資産 | 428,934 | 223,883 |
有価証券 | - | 300,000 |
商品 | 443,711 | 369,947 |
仕掛品 | 244,500 | 216,275 |
原材料及び貯蔵品 | 432,658 | 340,293 |
その他 | 425,460 | 188,695 |
貸倒引当金 | △144 | △144 |
流動資産合計 | 6,765,144 | 6,597,302 |
固定資産 | | |
有形固定資産 | | |
建物 | 45,241 | 27,050 |
減価償却累計額 | △37,368 | △21,063 |
建物(純額) | 7,873 | 5,986 |
機械及び装置 | 19,356 | 21,165 |
減価償却累計額 | △19,356 | △21,165 |
機械及び装置(純額) | 0 | 0 |
工具、器具及び備品 | 128,800 | 119,149 |
減価償却累計額 | △116,358 | △115,535 |
工具、器具及び備品(純額) | 12,442 | 3,614 |
有形固定資産合計 | 20,316 | 9,601 |
無形固定資産 | | |
その他 | 26,136 | 18,962 |
無形固定資産合計 | 26,136 | 18,962 |
投資その他の資産 | | |
投資有価証券 | 11,465 | 26,351 |
繰延税金資産 | 6,117 | 29,848 |
その他 | 116,954 | 130,832 |
投資その他の資産合計 | 134,538 | 187,032 |
固定資産合計 | 180,990 | 215,596 |
資産合計 | 6,946,134 | 6,812,899 |
| | (単位:千円) |
| 前連結会計年度 (2024年6月30日) | 当連結会計年度 (2025年6月30日) |
負債の部 | | |
流動負債 | | |
買掛金 | 206,654 | 191,051 |
未払法人税等 | 2,849 | 22,876 |
株主優待引当金 | - | 25,471 |
契約負債 | 235,496 | 326,937 |
その他 | 235,388 | 189,857 |
流動負債合計 | 680,389 | 756,194 |
固定負債 | | |
退職給付に係る負債 | 16,634 | 18,962 |
固定負債合計 | 16,634 | 18,962 |
負債合計 | 697,023 | 775,157 |
純資産の部 | | |
株主資本 | | |
資本金 | 1,836,587 | 1,836,587 |
資本剰余金 | 1,956,966 | 1,956,966 |
利益剰余金 | 2,439,317 | 2,228,621 |
自己株式 | △0 | △0 |
株主資本合計 | 6,232,871 | 6,022,175 |
非支配株主持分 | 16,239 | 15,566 |
純資産合計 | 6,249,110 | 6,037,741 |
負債純資産合計 | 6,946,134 | 6,812,899 |
E0536723850株式会社総医研ホールディングスSoiken Holdings Inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-07-012025-06-30FY2025-06-302023-07-012024-06-302024-06-301falsefalsefalse238502023-07-012024-06-30jpcrp_cor:UnallocatedAmountsAndEliminationMember238502023-06-30jppfs_cor:CapitalStockMember238502023-06-30jppfs_cor:CapitalSurplusMember238502023-06-30jppfs_cor:RetainedEarningsMember238502023-06-30jppfs_cor:ShareholdersEquityMember238502023-06-30jppfs_cor:NonControllingInterestsMember238502023-07-012024-06-30jppfs_cor:RetainedEarningsMember238502023-07-012024-06-30jppfs_cor:CapitalStockMember238502023-07-012024-06-30jppfs_cor:CapitalSurplusMember238502023-07-012024-06-30jppfs_cor:ShareholdersEquityMember238502023-07-012024-06-30jppfs_cor:NonControllingInterestsMember238502024-06-30jppfs_cor:CapitalStockMember238502024-06-30jppfs_cor:CapitalSurplusMember238502024-06-30jppfs_cor:RetainedEarningsMember238502024-06-30jppfs_cor:ShareholdersEquityMember238502024-06-30jppfs_cor:NonControllingInterestsMember238502025-06-30jppfs_cor:ShareholdersEquityMember238502025-06-30jppfs_cor:CapitalStockMember238502025-06-30jppfs_cor:CapitalSurplusMember238502025-06-30jppfs_cor:RetainedEarningsMember238502025-06-30jppfs_cor:NonControllingInterestsMember238502024-07-012025-06-30jppfs_cor:ShareholdersEquityMember238502024-07-012025-06-30jppfs_cor:CapitalStockMember238502024-07-012025-06-30jppfs_cor:CapitalSurplusMember238502024-07-012025-06-30jppfs_cor:RetainedEarningsMember238502024-07-012025-06-30jppfs_cor:NonControllingInterestsMember238502025-08-13238502025-06-30238502024-07-012025-06-30238502024-06-30238502023-07-012024-06-30238502023-06-30238502024-07-012025-06-30jpcrp_cor:ReportableSegmentsMember238502024-06-30jpcrp_cor:ReportableSegmentsMember238502023-07-012024-06-30jpcrp_cor:ReportableSegmentsMember238502025-06-30tse-acedjpfr-23850:ClinicalEvidenceServiceReportableSegmentsMember238502025-06-30tse-acedjpfr-23850:HealthCareSupportServiceReportableSegmentsMember238502025-06-30tse-acedjpfr-23850:FunctionalCosmeticRetailingReportableSegmentsMember238502025-06-30tse-acedjpfr-23850:FunctionalFoodRetailingReportableSegmentsMember238502025-06-30tse-acedjpfr-23850:FunctionalMaterialDevelopmentReportableSegmentsMember238502025-06-30jpcrp_cor:ReconcilingItemsMember238502024-07-012025-06-30tse-acedjpfr-23850:ClinicalEvidenceServiceReportableSegmentsMember238502024-07-012025-06-30tse-acedjpfr-23850:HealthCareSupportServiceReportableSegmentsMember238502024-07-012025-06-30tse-acedjpfr-23850:FunctionalCosmeticRetailingReportableSegmentsMember238502024-07-012025-06-30tse-acedjpfr-23850:FunctionalFoodRetailingReportableSegmentsMember238502024-07-012025-06-30tse-acedjpfr-23850:FunctionalMaterialDevelopmentReportableSegmentsMember238502024-07-012025-06-30jpcrp_cor:ReconcilingItemsMember238502024-06-30tse-acedjpfr-23850:ClinicalEvidenceServiceReportableSegmentsMember238502024-06-30tse-acedjpfr-23850:HealthCareSupportServiceReportableSegmentsMember238502024-06-30tse-acedjpfr-23850:FunctionalCosmeticRetailingReportableSegmentsMember238502024-06-30tse-acedjpfr-23850:FunctionalFoodRetailingReportableSegmentsMember238502024-06-30tse-acedjpfr-23850:FunctionalMaterialDevelopmentReportableSegmentsMember238502024-06-30jpcrp_cor:ReconcilingItemsMember238502023-07-012024-06-30tse-acedjpfr-23850:ClinicalEvidenceServiceReportableSegmentsMember238502023-07-012024-06-30tse-acedjpfr-23850:HealthCareSupportServiceReportableSegmentsMember238502023-07-012024-06-30tse-acedjpfr-23850:FunctionalCosmeticRetailingReportableSegmentsMember238502023-07-012024-06-30tse-acedjpfr-23850:FunctionalFoodRetailingReportableSegmentsMember238502023-07-012024-06-30tse-acedjpfr-23850:FunctionalMaterialDevelopmentReportableSegmentsMember238502023-07-012024-06-30jpcrp_cor:ReconcilingItemsMember238502025-06-30jppfs_cor:TreasuryStockMember238502024-07-012025-06-30jppfs_cor:TreasuryStockMember238502024-06-30jppfs_cor:TreasuryStockMember238502023-07-012024-06-30jppfs_cor:TreasuryStockMember238502023-06-30jppfs_cor:TreasuryStockMember238502024-07-012025-06-30jpcrp_cor:UnallocatedAmountsAndEliminationMember238502025-06-30jpcrp_cor:ReportableSegmentsMemberiso4217:JPYxbrli:pure